This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About ZOSTAVAX® (shingles (herpes zoster) vaccine live)

Updated on 12/04/2018

VACCINES

ZOSTAVAX is indicated for:1

  • Prevention of herpes zoster ("zoster" or shingles) and herpes zoster-related post-herpetic neuralgia (PHN) in the UK
  • Immunisation of individuals who are 50 years of age or older

Eligibility criteria

The National Immunisation Programme has eligibility criteria to determine which members of the population should be routinely offered the vaccine.

MSD believe that both the general population and healthcare professionals have a responsibility to ensure they are immunised, where possible, against preventable diseases throughout their lifetime. Vaccination schedules can be forgotten as there are less frequent offerings after childhood, and the information contained on this site is intended to support UK healthcare professionals to help immunise their suitable patients in a timely, resourceful manner using the appropriate product.

Posology/dosing1
Contraindications1
Interactions with other medicinal products1
Adverse events1

Useful links

Shingles Aware
Shingles Aware is a website developed, funded and maintained by MSD.

PHE Shingles Programme

PHE Shingles Vaccine Coverage Rate data

Green Book

Reference

  1. ZOSTAVAX Summary of Product Characteristics

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

VACC-1250414-0000 | Date of Preparation: April 2018